Position in LBRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$36,990,000
+$3,600,000 QoQ
Shares Held
1,500,000
0.0% QoQ
Ownership
5.23%
of shares outstanding
% of Portfolio
2.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LBRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Commodore Capital LP holds $1,469,900,983 across 32 Biotechnology names. LBRX ranks #15 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLAY |
Relay Therapeutics, Inc.
|
17,000,000 | $169,150,000 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
3,275,000 | $128,380,000 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
2,888,007 | $111,159,389 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
1,912,380 | $96,460,447 | |
| 5 | TYRA |
Tyra Biosciences, Inc.
|
2,475,000 | $94,792,500 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
2,696,616 | $85,536,659 | |
| 7 | NUVL |
Nuvalent, Inc.
|
833,600 | $85,402,320 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
750,000 | $62,467,500 |
All Filings in LBRX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $36,990,000 | 1,500,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $33,390,000 | 1,500,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $23,685,000 | 1,500,000 | Shares | Sole | 2025-11-14 | |
| 2025-09-11 | $21,192,500 | 1,225,000 | Shares | Sole | 2025-09-18 | |
| No filing history on record for this holder in this stock. | ||||||